BBIO Logo

BridgeBio Pharma, Inc. (BBIO) 

NASDAQ
Market Cap
$4.81B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
459 of 776
Rank in Industry
240 of 433

Largest Insider Buys in Sector

BBIO Stock Price History Chart

BBIO Stock Performance

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 …

Insider Activity of BridgeBio Pharma, Inc.

Over the last 12 months, insiders at BridgeBio Pharma, Inc. have bought $0 and sold $157.22M worth of BridgeBio Pharma, Inc. stock.

On average, over the past 5 years, insiders at BridgeBio Pharma, Inc. have bought $2M and sold $139.57M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 12,000 shares for transaction amount of $100,680 was made by Ellis Andrea () on 2022‑03‑15.

List of Insider Buy and Sell Transactions, BridgeBio Pharma, Inc.

2024-09-13Sale10 percent owner
5.8M
3.0339%
$25.75$149.35M-3.02%
2024-08-19SaleChief Executive Officer
27,389
0.0143%
$24.69$676,256+1.55%
2024-08-19SaleSecretary, Treasurer & CFO
4,155
0.0022%
$24.69$102,590+1.55%
2024-06-04Saledirector
1,500
0.0009%
$31.30$46,950-4.49%
2024-06-03Saledirector
1,000
0.0005%
$28.84$28,843-10.47%
2024-03-01Saledirector
2,500
0.0014%
$34.00$85,000-24.17%
2024-02-15Saledirector
2,915
0.0018%
$37.75$110,041-30.33%
2024-01-16Saledirector
2,915
0.0017%
$37.97$110,683-25.59%
2023-12-26Saledirector
100,000
0.0575%
$42.06$4.21M-33.73%
2023-12-18Saledirector
2,000
0.0012%
$40.00$80,000-26.98%
2023-12-15Saledirector
2,915
0.0015%
$36.12$105,290-28.00%
2023-12-01Saledirector
2,500
0.0014%
$29.40$73,500-7.19%
2023-11-17SaleCEO and President
51,552
0.0296%
$29.10$1.5M-2.27%
2023-11-17SaleSecretary, Treasurer & CFO
22,685
0.013%
$29.10$660,059-2.27%
2023-11-15Saledirector
2,915
0.0017%
$30.00$87,450-4.04%
2023-09-05Saledirector
2,500
0.0016%
$30.00$75,000-3.76%
2023-08-17SaleCEO and President
51,552
0.0322%
$28.59$1.47M+0.92%
2023-08-17SaleSecretary, Treasurer & CFO
22,683
0.0142%
$28.59$648,455+0.92%
2023-07-18Sale10 percent owner
1.5M
1.0576%
$35.00$52.5M-10.82%
2023-05-17SaleCEO and President
51,552
0.0336%
$14.01$722,218+104.55%

Insider Historical Profitability

<0.0001%
KKR Genetic Disorder L.P.10 percent owner
25260971
13.4343%
$25.6013+7.23%
STEPHENSON BRIAN CSecretary, Treasurer & CFO
85192
0.0453%
$25.60226+7.23%
Scott Randal W.director
4000
0.0021%
$25.6016
Valantine Hannahdirector
1764
0.0009%
$25.6024<0.0001%
VIKING GLOBAL PERFORMANCE LLC10 percent owner
26620991
14.1576%
$25.6010+6.17%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.